January 20, 2022
Life Sciences
  • A group of 27 generic drugmakers agreed to manufacture Merck & Co.’s COVID-19 antiviral pill in an effort to supply more than 100 lower-income countries with the treatment. According to the United Nations-backed Medicines Patent Pool, the drug should be “rapidly available” in those regions. As part of an earlier agreement, Merck and its partners won’t receive royalties for the pill while COVID-19 is considered an international public health emergency. (Article here)